Although trastuzumab and lapatinib are effective for metastatic BC patients with HER2-positive tumors [5–8], both primary (de novo) and acquired resistance to the HER2-targeted therapies frequently occur and currently represent a significant clinical challenge for successful treatment of HER2-positive BC [9]. The gene discussed is ERBB2; the disease is breast cancer.